title: [A case of liver metastasis of breast cancer responding to trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for 30 months].
abstract: In February, 19 9 8, a 48-year-old female patient underwent an operation for breast cancer. In November 2003, abdominal MRI revealed metastatic lesions in S 3 and S 5 of the liver, and chemotherapy (trastuzumab+weekly paclitaxel) was started, after which the metastatic lesions quickly reduced in size. No lesions could be detected by April 2004, and she was diagnosed as a complete response (CR). She now visits our hospital as an outpatient without any evidence of recurrence or any side effects of chemotherapy for 8 years and 8 months after surgery. For advanced breast cancer, there is no standard criteria regarding the time when to stop chemotherapy after obtaining a CR. This time, we experienced a case of liver metastasis of breast cancer responding to a regimen of trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for a long period. We discuss the timing of the termination of chemotherapy in such a case in light of our experience and the literature.
authors: Department of Surgery, Kurashiki Central Hospital.
authors: Yoshio
authors: Y
authors: Nagahisa
authors: Shiro
authors: S
authors: Imai
authors: Kazushige
authors: K
authors: Yamaguchi
authors: Michio
authors: M
authors: Okabe
authors: Atsushi
authors: A
authors: Tsuruta
authors: Kazuyuki
authors: K
authors: Kawamoto
authors: Mototaka
authors: M
authors: Niwano
authors: Kaoru
authors: K
authors: Sano
authors: Taebun
authors: T
authors: Park
authors: Yasuo
authors: Y
authors: Yoshida
authors: Tadashi
authors: T
authors: Ito
authors: Keizo
authors: K
authors: Ogasahara
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab; D017239:Paclitaxel